De-Risking a Rare Disease Launch Starts with Precision June 25, 2026Posted inBiotechnology Why traditional models fall short in rare disease commercialization—and what works instead. Post navigation Previous Post Otsuka posts phase 3b ADHD trial win ahead of looming FDA approval decisionNext PostInduPro Licenses Lonza’s Linker Payload Technologies and Bioconjugation Platforms
